Name Patrick W. Serruys
Country Netherlands
Job Interventional Cardiologist

Other summitMD.com content(s) by This Presenter

  1. Drug Eluting Stent- The Beginning of the End or the End of the Beginning
  2. VH and OCT of Biodegradable Solution Stent
  3. DELFT Registry and LM SYNTAX Update
  4. Mortality After PCI with BMS and DES from the Thoraxcentre Database
  5. SYNTAX - Data Synthesis and Clinical Recommendations
  6. SYNTAX: Anatomic Complexity Determines PCI Outcomes (Practical Use of the SYNTAX Score)
  7. Time to Move into Stenting in All Patients !
  8. Perspective of LM Stenting with Current Registry and Randomized Clinical Data
  9. Diabetic Patients with Multivessel Disease: Stents or Surgery?
  10. Vulnerable Plaque Trials Using Surrogate Imaging Marker
  11. Assessment of LEADERS 12 Months Result
  12. LEADERS: Analysis of 9 Months OCT Results
  13. Systemic Therapy for Plaque Stabilization: New Drugs Targeting LP-PLA2
  14. SYNTAX - Data Synthesis and Clinical Recommendations
  15. Complications after TAVI: VARC Definitions, Frequency, and Management Considerations
  16. Will Bioabsorbable Stents Transform PCI in the Future?
  17. Updated Guideline of LM PCI: Three-Year Follow-up of SYNTAX LM Subgroup Analysis
  18. BIOMATRIX: Learned from the Three-Year LEADERS Trial
  19. Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes
  20. Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents
  21. New Metallic DES: Bioresorbable Polymers or Polymer-Free
  22. Theoretical Construct: Why BRS May Change the Landscape of Coronary Intervention?
  23. Serial Follow-up Imaging of Bioresorbable Vascular Scaffolds and Clinical Implication
  24. Future of BRS
  25. Yes, It Can Replace Metal Stent.
  26. Unrestricted Adoption in Real World Patients Is Possible.
  27. SURTAVI: Transaortic Valve Replacement Compared to Surgical Aortic Valve Replacement in Medium-Risk Patients
  28. Unprotected Left Main Coronary Disease: Thoughtful Insights
  29. Multi Slide Findings in More Than 1000 Consecutive Patients for TAVR
  30. BRS Mechanical Properties: From Bench to Bedsides
  31. Left-Main Disease Population
  32. Forecasting Mortality in Left-Main Disease with the Syntax Score II Model Applied to the EXCEL Trial
  33. Next BRS: What Are Going to Change?
  34. ABSORB in STEMI Trofi II
  35. Grand Vision for BRS Future: Natural History and Clinical Implication
  36. SYNTAX-1, SYNTAX-II, SYNTAX-III: From Invasive to Non-Invasive Assessment of Coronary Stenosis
  37. Pitfalls with Comparative Assessment of BRS and DES with Angio, IVUS and OCT
  38. Trans-Apical Mitral Valve of Sinomed
  39. Are Outcomes Following CABG for Left Main Disease Improving Over the Last Decade: A Propensity Matched Analysis from the EXCEL and SYNTAX Randomized Trials
  40. The History of 40 Years of PTCA
  41. Gender in EXCEL
  42. Is TAVR with STS from
  43. Can Improved Scaffold Technology Reduce Clinical Complications?: Insights and Speculation
  44. The Future of Coronary Imaging and Coronary Physiology
  45. Lessons from SYNTAX II: Improving Decision Making in the SYNTAX III Trial
  46. Ticagrelor Monotherapy in GLOBAL-LEARDERS and TWILIGHT: Interpretation and Clinical Implication
  47. Short DAPT Trials with Contemporary/Future DES: What Do We Expect?
  48. SYNTAX II: Impact of Physiology and Imaging on PCI Outcome
  49. [Special Lecture] Angiography for Assessment of Regurgitation Post TAVR: The Minimalist Approach and the Return of the Jedi
  50. Long-term(10-Year) Validation of the SYNTAX-II 2020 Score
  51. Comparative Assessment of Aortic Regurgitation Post TAVR in (9) Commercially Available THV\'s